FDA Inspection 1222115 — Hikma Pharmaceuticals USA Inc.
The FDA completed an inspection of Hikma Pharmaceuticals USA Inc. on November 3, 2023 in Cherry Hill, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- November 3, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Cherry Hill, NJ (United States)